Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma

(2019) Katharine E.H. Thomas et al.   ONCOLOGIST

Therapeutic Options for Neuroendocrine Tumors

(2019) Reto M. Kaderli et al.   JAMA Oncology

Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors

(2019) A. Tuba Kendi et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Quality of life in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy: information from a monitoring program in clinical routine

(2018) Caroline Martini et al.   JOURNAL OF NUCLEAR MEDICINE

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR

(2018) David Cella et al.   CLINICAL THERAPEUTICS

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate

(2017) Tessa Brabander et al.   ENDOCRINE-RELATED CANCER

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

(2017) Rodney J. Hicks et al.   NEUROENDOCRINOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

(2016) Dieter Hörsch et al.   EUROPEAN JOURNAL OF CANCER

Peptide Receptor Radionuclide Therapy: An Overview

(2015) Ashutosh Dash et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

(2014) Camilla Bardram Johnbeck et al.   Future Oncology

Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2014) S. Ezziddin et al.   JOURNAL OF NUCLEAR MEDICINE

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

(2013) John J. Zaknun et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2011) S. Ezziddin et al.   JOURNAL OF NUCLEAR MEDICINE

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)

(2010) R. Garcia-Carbonero et al.   ANNALS OF ONCOLOGY

Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut

(2009) Jonathan Strosberg et al.   NEUROENDOCRINOLOGY

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

(2008) Bart de Keizer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY